Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, Kudo M. Kim SR, et al. Among authors: kim ki. Digestion. 2011;84 Suppl 1:5-9. doi: 10.1159/000333208. Epub 2011 Dec 2. Digestion. 2011. PMID: 22156479
Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, Hotta H, Shouji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y. Sasase N, et al. Among authors: kim sr, kim ki. Intervirology. 2008;51 Suppl 1:70-5. doi: 10.1159/000122601. Epub 2008 Jun 10. Intervirology. 2008. PMID: 18544951
Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, Kudo M. Kim SR, et al. Among authors: kim ki. Digestion. 2011;84 Suppl 1:10-6. doi: 10.1159/000333209. Epub 2011 Dec 2. Digestion. 2011. PMID: 22156480
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Sugimoto K, Kim SR, El-Shamy A, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, Kudo M. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Dig Dis. 2013;31(5-6):434-9. doi: 10.1159/000355241. Epub 2013 Nov 21. Dig Dis. 2013. PMID: 24281017 Clinical Trial.
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Oncology. 2015;89 Suppl 2:42-6. doi: 10.1159/000440630. Epub 2015 Nov 19. Oncology. 2015. PMID: 26584035
4,837 results